Domantis pockets $29M in new venture funds

Domantis has raised $29 million in new venture funds. New investors Novo Nordisk and MC Life Science Ventures--a subsidiary of Mitsubishi Corporation--led the round. "Domantis' twelve lead programs are based on novel dAb products for treating major diseases including COPD, rheumatoid arthritis, asthma and colorectal cancer," said Domantis CEO Robert Connelly. "This financing, together with the growing revenue stream from our nine partnerships, provides sufficient resources to fund the clinical development of these programs." Domantis is based in Waltham, MA and the UK.

- read this release for more information

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.